Dealing with behavioral and psychological symptoms of dementia: a general overview

Majda Azermai
Heymans Institute of Pharmacology, Ghent University, Ghent, Belgium

Abstract: Dealing with the behavioral and psychological symptoms of dementia (BPSD) is often complex. Given the controversy with regard to antipsychotics for behavioral problems in people with dementia, there has been a renewed emphasis on nonpharmacological interventions, with progress in the design of the relevant studies. Potential nonpharmacological interventions for BPSD are: cognitive training/stimulation, rehabilitative care, activities of daily living, music therapy, massage/touch, physical activity, education/training of professionals, and education and psychosocial support of informal caregivers. Use of antipsychotics in the management of BPSD is controversial due to limited efficacy and the risk of serious adverse effects, but credible alternatives remain scarce. The problem of chronic use of antipsychotics in nursing homes should be tackled. Discontinuation of antipsychotic medication in older individuals with BPSD appears to be feasible. Discontinuation efforts are needed to differentiate between patients for whom antipsychotics have no added value and patients for whom the benefits outweigh the risks.

Keywords: behavioral symptoms, psychological symptoms, dementia, interventions, nonpharmacological intervention

Introduction
As our population grows older, one of the most common chronic mental health conditions is dementia. By 2020, it is estimated that there will be 35 million cases worldwide. Dementia, with Alzheimer’s disease as the most common cause, is a progressive illness affecting cognitive functions. The cognitive impairment is often accompanied by behavioral and psychological symptoms of dementia (BPSD). These symptoms tend not to occur in isolation, and are likely to be present in clusters that can vary by time, severity, and diagnosis. There is a certain degree of concordance in the groups of BPSD, resulting in four syndromes: hyperactivity cluster (agitation, aggression, euphoria, disinhibition, irritability, aberrant motor activity), psychosis cluster (hallucinations and delusions), mood liability cluster (depression and anxiety), and instinctual cluster (appetite disturbance, sleep disturbance, and apathy). It is estimated that almost all older individuals with dementia will develop BPSD at some point during progression of their illness. The behavioral problems rather than the cognitive problems are important contributing factors for caregiver burden and institutionalization. Management of BPSD is very complex for families and health care professionals. Use of antipsychotics for the management of BPSD is controversial due to limited efficacy and the risk of serious adverse effects, but credible alternatives remain scarce. In this paper, we provide a general overview of the nonpharmacological
treatment options and associated difficulties, and discuss the controversy with regard to antipsychotics.

**Nonpharmacological treatment options**

Dementia guidelines recommend use of nonpharmacological interventions as first-line treatment options. Individual interventions are generally not supported by the majority of guidelines, and the recommendations in the guidelines acknowledge the low quality of supporting evidence. Overall, there is an insufficient level of agreement between the guidelines regarding specific nonpharmacological options, rendering decision-making on nonpharmacological interventions extremely difficult. Possible nonpharmacological options traditionally suggested by the guidelines include aromatherapy, multisensory stimulation, therapeutic use of music, animal-assisted therapy, and massage, but often come with the recommendation that more research is needed. However, since 2005, there has been intense debate on the risks/benefits of antipsychotics in BPSD, which has resulted in a renewed emphasis on nonpharmacological treatment options. In a report from the Belgian Health Care Knowledge Center, nonpharmacological options for the management of dementia were thoroughly reviewed. This resulted in a systematic review including: cognitive training/stimulation, rehabilitative care, activities of daily living (ADL), music therapy, massage/touch, physical activity, education/training of professionals, and education and psychosocial support of informal caregivers.

The methodological quality of selected randomized controlled trials was rated using the appropriate Scottish Intercollegiate Guidelines Network tools. The risk of bias in the included randomized controlled trials was assessed by three independent reviewers based on well-defined criteria. The quality of the evidence was rated according to the Grading of Recommendations Assessment, Development, and Evaluation system. More information on the methodology used in this systematic review can be found in Kroes et al.

Overall, most of the nonpharmacological interventions were promising, but more research is still needed. For reality orientation, there was a lack of high-quality studies and a low level of evidence for this intervention. For cognitive stimulation/training, there was moderate quality of evidence, with a mild to moderate effect on specific outcomes, such as cognitive function, ADL, behavior, and mood. For reminiscence therapy, the studies included in the systematic review showed positive results on cognition, behavior,
people with dementia. This warning was based on the results of a pooled analysis of 17 randomized controlled trials, which reported a 1.7 times increased risk of mortality with atypical antipsychotic use in older adults with dementia when compared with placebo. In 2008, the FDA extended this warning to all antipsychotics. Other adverse effects, such as stroke, falls and consequent fractures, cognitive decline, and deep vein thrombosis, have been reported in association with the use of antipsychotics in older persons, even in short-term trials (up to 12 weeks), while antipsychotics are used for far longer in clinical practice. Therefore, serious concerns exist with regard to the long-term effects of these agents. In 2009 in the UK, Banerjee concluded that there was minimal evidence for improvement in global behavioral disturbance using antipsychotics (effect size 0.1–0.2), but a significant increase in absolute mortality risk. In the same year, Kleijer et al reported that only 18% of patients with dementia started on antipsychotics showed improvement in their behavior, while 49% deteriorated. The potential for benefit is overshadowed by the potential for harm, making the use of antipsychotics controversial for older people with dementia.

More recently, there have been updates regarding the off-label use of atypical antipsychotics for elderly patients with dementia, such as the comparative effectiveness reviews issued by the Agency for Healthcare Research and Quality in the USA. It was concluded that there were small but statistically significant benefits using aripiprazole, olanzapine, and risperidone in the treatment of BPSD. Adverse events were common, and included death, stroke, and extrapyramidal and urinary symptoms. Although the use of antipsychotics in BPSD is off-label, antipsychotics are still the best pharmacological short-term treatment option for severe persistent symptoms of dementia-related aggression/agitation.

The advice in the guidelines is to minimize antipsychotic use in older people with dementia, to initiate antipsychotics only in patients with severe distress after a risk-benefit analysis, and to limit the dose and treatment duration, with attempts at discontinuation.

However, strong barriers to discontinuing antipsychotics exist in clinical practice. In our own study, we found that 13.8% and 12.2% of nurses and general practitioners, respectively, showed a willingness to discontinue antipsychotics in a small proportion of chronic users (nursing home residents), with a shared willingness in only 4.2%. Residents in whom there was a greater willingness to attempt discontinuation of antipsychotic medication were generally older (mean age 84.6 versus 80.3 years, \( P=0.07 \)), were more physically dependent (ADL >14, 93.3% versus 60.9%, \( P=0.01 \)), and were resident in a ward with controlled access (80.0% versus 45.7%, \( P=0.02 \)). In contrast, residents for whom there was significantly less willingness to discontinue antipsychotic medication already had a previously failed discontinuation effort and were at risk of causing harm to themselves or to others. Nurses working longer on the ward with lower education had higher barriers to discontinuation of antipsychotics.

**Discussion**

Dealing with BPSD is complex. Despite limited consensus on efficacy, evidence-based guidelines recommend pharmacological options first, and after a proven lack of efficacy, pharmacological treatment may be considered. Given the controversy with regard to antipsychotics for behavioral problems in people with dementia, there is a renewed emphasis on pharmacological interventions with progress in the design of relevant studies. Use of “person-centered care” is becoming more common in residential homes, with some positive results in reducing antipsychotic medication and symptoms of agitation. However, the effects on quality of life remain unclear. Also, in the WHELD trial, person-centered care training remained the focus, but it is combined with social intervention, exercise, and formal antipsychotic review. In the WHELD trial, health professionals developed the specific skills needed to offer quality of care to people with dementia.

In this way, they developed a comprehensive staff training intervention, aiming to improve the quality of life for people with dementia living in care homes.

Other potential nonpharmacological interventions for BPSD include cognitive training/stimulation, rehabilitative care, music therapy, massage/touch, physical activity, and education/training for professionals, and education and psychosocial support for informal caregivers. The common belief that nonpharmacological interventions can be equally effective across the severity levels of dementia might be erroneous, since some studies have reported that older persons with advanced dementia respond differently to such interventions. Pharmacological treatment with antipsychotics often remains the first-line treatment when dealing with BPSD.

There is agreement among the guidelines regarding the use of risperidone, olanzapine, and haloperidol, with claims for efficacy supported by high-quality studies. When looking closer into the primary evidence for the efficacy of antipsychotics in BPSD, there is modest efficacy for haloperidol in terms of aggression. With regard to the atypical antipsychotics (the best researched
being risperidone and olanzapine), there is modest efficacy for aggression and psychosis, but the evidence with regard to efficacy for other BPSD symptoms is not convincing.\textsuperscript{15} Although the use of antipsychotics for BPSD is off-label, antipsychotics are still the best short-term pharmacological option for severe and persistent symptoms of dementia-related aggression/agitation.

Chronic use of antipsychotics, especially in nursing home residents, should be discouraged. Abrupt discontinuation of antipsychotics in older individuals with BPSD appears to be feasible. Discontinuation efforts are needed to differentiate between patients for whom antipsychotics have no added value and patients for whom the benefits outweigh the risks.

**Disclosure**

The author reports no conflicts of interest in this work.

**References**
